Rogers will formally retire once the succession process is completed. The Sunnyvale, California-based company is working with executive search firm Spencer Stuart to find a replacement CEO.
“I’d like to thank Erica for her tremendous contributions to Silk Road over the last 11 years. Erica has been integral in leading and expanding the company’s strong operational infrastructure and commercial enterprise and driving a significant expansion of the use of Transcarotid Artery Revascularization (TCAR) and its impact on patients. She also has created an enduring, mission-focused culture at Silk Road, setting the Company apart,” Silk Road Chair Jack Lasersohn said in a news release. “The Silk Road Medical senior leadership team and Board of Directors are well-prepared for Erica’s transition. We plan to work closely together to ensure a smooth process as we drive continued growth in the business.”
Rogers joined the company in October 2012 as president and CEO. She has spent the majority of her career in executive leadership roles. In addition to holding the corner office at Silk Road Medical, Rogers is a director at HistoSonics and Sight Sciences and an investment advisor for Venture Investors. She’s also held roles of varying responsibility at Medicines360, Nanosys, Allux Medical, Visiogen and Boston Scientific.
“It has been an honor to work with the Silk Road team through more than a decade of progress toward improving patients’ lives,” Rogers said. “I’m incredibly proud of the foundation we’ve built, our amazing employees, and our undeniable leadership in carotid artery disease innovation. We have set the stage for an exciting future for the Company. I look forward to supporting a smooth transition and cheering on our team as they continue to promote TCAR as the gold standard in stroke prevention.”
